<DOC>
	<DOCNO>NCT01215084</DOCNO>
	<brief_summary>The primary objective study determine Pharmacokinetic ( PK ) safety profile fampridine-PR 10 mg Chinese Japanese adult healthy volunteer . The secondary objective study compare PK safety profile fampridine-PR 10 mg among Chinese , Japanese , Caucasian adult healthy volunteer .</brief_summary>
	<brief_title>A Pharmacokinetics ( PK ) Safety Study Oral Fampridine-PR 10 mg Chinese , Japanese , Caucasian Adult Healthy Volunteers</brief_title>
	<detailed_description>The Caucasian group include allow comparison pharmacokinetic safety data different race group perform data obtain study control condition .</detailed_description>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Subjects Chinese Japanese origin ( least maternal paternal grandparent Chinese Japanese origin , respectively ) , Caucasian subject . Japanese subject Japanese diet regular basis . All male subject female subject childbearing potential must practice effective contraception study willing able continue contraception 4 week single dose study treatment . Body Mass Index ( BMI ) within range 18.5 30 kg/m2 ( inclusive ) . Normal urinalysis result determine Investigator follow parameter : protein , glucose , specific gravity , ketone , urobilinogen , bilirubin , pH , blood . Normal 12lead ECG determine Investigator . Key Known history human immunodeficiency virus ( HIV ) infection positive test result HIV antibody . Known history hepatitis B hepatitis C infection , hepatitis B carrier ( positive test result Hepatitis B Surface Antigen [ HBsAg ] ) , hepatitis C infection ( positive test result Hepatitis C virus antibody [ HCV Ab ] ) . Psychiatric neurological disorder . History epilepsy convulsive disorder . Any cardiovascular , renal , gastrointestinal , respiratory , metabolic disorder , major disease , determine Investigator . Clinically significant abnormal hematology blood chemistry value Screening , determine Investigator ; screen value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 1.5 time great upper limit normal ; clinically significant ( determined Investigator ) elevate screen value bilirubin creatinine ; creatinine clearance lower 80 mL/minute ; low screening value platelet hemoglobin ; normal range white blood cell ( WBC ) . History alcohol abuse ( define Investigator ) within previous 2 year , blood screen positive alcohol . History drug abuse ( define Investigator ) within previous 2 year , urine screen positive cannabinoids , barbiturate , amphetamine , benzodiazepine . Premalignant malignant disease . History clinically significant severe allergic anaphylactic reaction . Known allergy pyridinecontaining substance . Active bacterial viral infection within previous month . Female subject pregnant currently breastfeed . Previous participation another investigational drug study within last 3 month . Treatment prescription medication within 28 day prior Day 1 . ( Treatment pharmaceuticalgrade vitamin allow provide dose regimen stable 28 day prior Day 1 . ) Treatment overthecounter product , include herbalcontaining and/or caffeinecontaining preparation , and/or alternative health preparation procedure within 2 day prior Day 1 . Donation blood ( 500 mL great ) within 56 day prior study dose plasma donation within 7 day prior study dose . Inability comply study requirement . Other unspecified reason , opinion Investigator Biogen Idec , make subject unsuitable enrollment . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Human Volunteers</keyword>
</DOC>